Further strategies in the development of anti-cancer compounds targeting ovarian malignancies include the suppression of proteins that affect the mTOR cascade, using siRNA[95], or the inactivation of AKT, PI3K, or simultaneous block of mTOR and PI3K, designing dual mTOR/PI3K inhibitors. This evidence concerns the gene MTOR and cancer.